首页|重组组织型纤溶酶原激活剂治疗心肌梗死合并室性心律失常的效果观察

重组组织型纤溶酶原激活剂治疗心肌梗死合并室性心律失常的效果观察

扫码查看
目的:探究重组组织型纤溶酶原激活剂治疗心肌梗死合并室性心律失常的疗效及对炎性因子的影响.方法:选取2021年2月—2023年2月在本院接受治疗的心肌梗死合并室性心律失常患者74例,应用随机数表法将其分为对照组及观察组,各37例.对照组接受尿激酶治疗,观察组接受重组组织型纤溶酶原激活剂治疗,比较两组心率(HR)、血压[收缩压(SBP)、舒张压(DBP)]、血清N末端B型利钠肽前体(NT-proBNP)、血管内皮[血清一氧化氮(NO)、血管性假血友病因子(vWF)、内皮素(ET-1)]、心功能[左心室舒张末期内径(LVEDD)、左心室收缩末径(LVSED)、左室射血分数(LVEF)]、血清炎症因子[白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子(TNF-α)]、氧化应激[丙二醛(MDA)、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GPX)].结果:治疗后,观察组HR、SBP、DBP、NT-proBNP、vWF、ET-1、LVEDD、LVSED、IL-6、hs-CRP、TNF-α、MDA水平低于对照组,NO、LVEF、SOD、GPX水平高于对照组(P<0.05).结论:心肌梗死合并室性心律失常患者采用重组组织型纤溶酶原激活剂治疗的效果良好,可降低心率、血压、血清N末端B型利钠肽前体水平,改善患者血管内皮功能、心功能、氧化应激状态,降低炎症因子水平.
Effect Observation of Recombinant Tissue Plasminogen Activator in the Treatment of Myocardial Infarction Complicated with Ventricular Arrhythmia
Objective:To explore the efficacy of recombinant tissue plasminogen activator in the treatment of myocardial infarction complicated with ventricular arrhythmia and its effect on inflammatory factors.Methods:A total of 74 patients with myocardial infarction complicated with ventricular arrhythmia who were treated in our hospital from February 2021 to February 2023 were selected and divided into control group and observation group by random number table method,with 37 patients in each group.The control group was treated with urokinase,and the observation group was treated with recombinant tissue plasminogen activator.Heart rate(HR),blood pressure[systolic blood pressure(SBP),diastolic blood pressure(DBP)],serum N-terminal B-type natriuretic peptide precursor(NT-proBNP),vascular endothelium[serum nitric oxide(NO),von Willebrand factor(vWF),endothelin(ET-1)],cardiac function[left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVSED),left ventricular ejection fraction(LVEF)],serum inflammatory factors[interleukin-6(IL-6),high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor(TNF-α)],oxidative stress[malondialdehyde(MDA),superoxide dismutase(SOD),glutathione peroxidase(GPX)]were compared between the two groups.Results:After treatment,the levels of HR,SBP,DBP,NT-proBNP,vWF,ET-1,LVEDD,LVSED,IL-6,hs-CRP,TNF-α and MDA in the observation group were lower than those in the control group,and the levels of NO,LVEF,SOD and GPX were higher than those in the control group(P<0.05).Conclusion:Recombinant tissue plasminogen activator is effective in the treatment of patients with myocardial infarction complicated with ventricular arrhythmia,which can reduce heart rate,blood pressure,serum N-terminal B-type natriuretic peptide precursor level,improve vascular endothelial function,cardiac function,oxidative stress status,and reduce inflammatory factor levels.

Recombinant tissue plasminogen activatorMyocardial infarctionVentricular arrhythmiaInflammatory factor

张书翔、吕海科、殷荣磊、刘成群

展开 >

方城县人民医院心内科,河南 南阳 473200

重组组织型纤溶酶原激活剂 心肌梗死 室性心律失常 炎症因子

2024

中国药物滥用防治杂志
中国药物滥用防治协会 军事医学科学院毒物药物研究所

中国药物滥用防治杂志

影响因子:0.584
ISSN:1006-902X
年,卷(期):2024.30(6)
  • 3